Sign In
Last checked at 
4 Dec 2020 16:44
04 December 2020
SkinBioTherapeutics plc
Director Dealing
The Company was informed today that on 4 December 2020 the CFO of the Company, Doug Quinn and persons closely associated with him, sold 253,190 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 16 pence per Ordinary Share and then repurchased, into their ISAs, 248,220 Ordinary Shares at a price of 16.02 pence per Ordinary Share to facilitate ISA transfers.
For more information please contact:
SkinBioTherapeutics plc | Tel: +44 (0) 161 468 2760 |
Stuart Ashman, CEO Doug Quinn, CFO | |
Cenkos Securities plc (Nominated Adviser & Broker) | Tel: +44 (0) 20 7397 8900 |
Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales) | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis | SkinBio@instinctif.com
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit:www.skinbiotherapeutics.com.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Doug Quinn | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870 | |||||
b. | Nature of the transaction | Sale of shares | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
16p |
126,595 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 4th December 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Doug Quinn | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870 | |||||
b. | Nature of the transaction | Purchase of shares | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
16.02 |
124,110 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 4th December 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Bernadette Quinn | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Spouse of Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870 | |||||
b. | Nature of the transaction | Sale of shares | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
16p |
126,595 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 4th December 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Bernadette Quinn | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Spouse of Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870 | |||||
b. | Nature of the transaction | Purchase of shares | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
16.02 |
124,110 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 4th December 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||
Follow the stocks
